Title:
ANTIBODY CAPABLE OF BINDING TO NEW CORONAVIRUS (SARS-COV-2)
Document Type and Number:
WIPO Patent Application WO/2023/190852
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a novel antibody that can prevent and/or treat COVID-19 infection. Provided is an antibody that has a heavy-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 1, a heavy-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 2, a heavy-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 3, a light-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 4, a light-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 5, and a light-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 6 and can bind to a S1 subunit of SARS-CoV-2, or a antibody fragment of the antibody.
Inventors:
WATANABE SHINYA (JP)
IMAI JUNICHI (JP)
SHIGA HATSUKI (JP)
SATO SHIGEKO (JP)
MATSUKURA SUSUMU (JP)
HOSHI HIROTAKA (JP)
IMAI JUNICHI (JP)
SHIGA HATSUKI (JP)
SATO SHIGEKO (JP)
MATSUKURA SUSUMU (JP)
HOSHI HIROTAKA (JP)
Application Number:
PCT/JP2023/013146
Publication Date:
October 05, 2023
Filing Date:
March 30, 2023
Export Citation:
Assignee:
PUBLIC UNIV CORPORATION FUKUSHIMA MEDICAL UNIV (JP)
MEDICROME INC (JP)
FUKUSHIMA CELL FACTORY INC (JP)
MEDICROME INC (JP)
FUKUSHIMA CELL FACTORY INC (JP)
International Classes:
C12N15/13; A23L33/17; A41D13/11; A61K8/64; A61K39/395; A61P31/14; A61Q17/00; A62B18/02; C07K16/10; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/63; C12P21/08
Domestic Patent References:
| WO2021045836A1 | 2021-03-11 |
Foreign References:
| KR102229225B1 | 2021-03-19 | |||
| KR102205028B1 | 2021-01-20 | |||
| CN111592594A | 2020-08-28 |
Attorney, Agent or Firm:
MUTSUKI PARTNERS (JP)
Download PDF: